Beth Israel Deaconess Medical Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Beth Israel Deaconess Medical Center sits in the top decile of US sponsors by registered trial count (#75 of 15,742 sponsors by registered trial count).
Beth Israel Deaconess Medical Center: 488 sponsored US clinical trials, 66 recruiting.
Beth Israel Deaconess Medical Center sponsors 488 registered US clinical trials on ClinicalTrials.gov, 66 of them currently recruiting, and 321 completed. 45 of these trials are in Phase 3-4 (later-stage) and 144 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 8 trials.
Top-decile sponsor footprint
Beth Israel Deaconess Medical Center ranks in the top decile of sponsors by registered trial count (#75 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
321 of 380 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
488 total, page 2 of 10
Mind Body Syndrome Therapy for Chronic Pain
NCT04689646
Safety and Efficacy of Endovascular Repair of Complex Aortic Pathology With Physician-modified Endovascular Grafts (PMEGs)
NCT04746677
Gastric Emptying of Water and Sports Drink in Labor
NCT04229043
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
NCT04288427
Pancreatic Cancer Screening for At-risk Individuals
NCT05006131
Statins In Intracerbral Hemorrhage
NCT03936361
The Physiology of Human Brown Adipose Tissue
NCT04352244
Treating Hyperexcitability in AD With Levetiracetam
NCT03875638
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
NCT02926729
Purinergic Signaling and the Postmenopausal Heart
NCT06015776
Prevalence and Impact of Obstructive Sleep Apnea in Multiple Sclerosis
NCT04603196
The Effect of Sleep Deprivation and Recovery Sleep on Emotional Memory and Affective Reactivity
NCT03767426
Gait Analysis in Neurological Disease
NCT02994719
Hematoma Block for Distal Radius Fracture
NCT02346929
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
NCT01890590
Biomarkers in Infection
NCT02545478
NMBA Reversal and Postoperative Urinary Retention
NCT06948409
Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID
NCT06597396
Online Tai Chi Plus Fitbit After ACS
NCT05699642
Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana
NCT05986084
Feasibility of the Comfort Measures Only Time Out (CMOT)
NCT05861323
Prospective Validation of an EHR-based Pancreatic Cancer Risk Model
NCT05973331
Prospective Validation of Liver Cancer Risk Computation (LIRIC) Models
NCT06140823
Understanding Components of Mind-body Exercise for Physical Activity Engagement in Metabolic Syndrome
NCT05242640
Evaluation of a Novel Class of Objective Myofascial Pain Assessments
NCT05793086
Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression
NCT05683964
Pectoral Nerve Blocks (PECs) for Cardiovascular Implantable Electronic Device Placement
NCT05283980
Groceries for Black Residents of Boston to Stop Hypertension Among Adults With Treated Hypertension
NCT05393232
Pain in Long COVID-19: the Role of Sleep
NCT05606211
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
NCT05121337
Postoperative VR for Recovery After Bariatric Surgery
NCT04754165
Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial
NCT04835506
PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients
NCT04093219
Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
NCT03637543
Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients
NCT03679650
Identification of Genetic Causes of Calcific Aortic Valve Disease
NCT04149600
Sleep and Inflammatory Resolution Pathway
NCT03377543
3D Printer Modified CPAP Mask for Obstructive Sleep Apnea
NCT03932383
Olaparib In Metastatic Breast Cancer
NCT03344965
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission
NCT03059485
Saxenda: Underlying Mechanisms and Clinical Outcomes
NCT02944500
Utility of Cortical Bone Tissue Properties in the Assessment of Fracture Risk
NCT03076034
Lorcaserin in Obesity: Identification of CNS Targets Using FMRI
NCT02400359
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02204085
Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
NCT01067287
Biomechanics of Metastatic Defects in Bone
NCT02109952
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod
NCT00799110
Characterization of Prostate Cancer With 3T MR
NCT00831142
Blood Flow MRI for Monitoring Brain Tumors
NCT01538264
Efficacy and Safety of 500mg of Fulvestrant
NCT00585507
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 53 |
| Phase 2 | 91 |
| Phase 3 | 13 |
| Phase 4 | 32 |
Therapeutic Areas
What is open in the Beth Israel Deaconess Medical Center pipeline
66 recruiting of 488 indexed (14% open); 321 completed (66%).
Phase mix: 45 late (III/IV) vs 144 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (8 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Beth Israel Deaconess Medical Center: open-pipeline peers nationwide
Peers matched on 488 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Beth Israel Deaconess Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 488 trials (± recruiting share)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- Fred Hutchinson Cancer Center · 483 trials · 12% recruiting
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Case Comprehensive Cancer Center · 14% recruiting · 407 trials
- Wayne State University · 13% recruiting · 163 trials
- University of Michigan · 13% recruiting · 1,327 trials
- Albany Medical College · 13% recruiting · 52 trials
Related
What to do with this Beth Israel Deaconess Medical Center page
488 registered trials is a research-attention snapshot, not an endorsement of Beth Israel Deaconess Medical Center or any single study.
- 66 of Beth Israel Deaconess Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Beth Israel Deaconess Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Beth Israel Deaconess Medical Center pipeline card: 488 registered trials from official public datasets.Report a data error.